ThaiPR.NET https://www.thaipr.net/location/aberdeen-scotland-and-singapore Press Release Distribution Center of Thailand Thu, 30 Apr 2026 18:05:11 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development]]> https://www.thaipr.net/en/health_en/3275346 Thu, 01 Dec 2022 08:45:20 +0700 health_en https://www.thaipr.net/en/health_en/3275346 – Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities – Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco – For people with early […]

The post LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development appeared first on ThaiPR.NET.

]]> <![CDATA[TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions]]> https://www.thaipr.net/en/health_en/3249461 Thu, 06 Oct 2022 17:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3249461 For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals For people with mild to moderate Alzheimer’s, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with AD HMTM […]

The post TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions appeared first on ThaiPR.NET.

]]> <![CDATA[TauRx’s late-stage clinical trial reaches new milestone]]> https://www.thaipr.net/en/health_en/3180078 Mon, 18 Apr 2022 09:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3180078 – Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer’s – TauRx on track to announce top line results in May – Trial aims to confirm efficacy of first tau-based treatment for Alzheimer’s TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease (AD) research, has announced that the last patient has completed treatment […]

The post TauRx’s late-stage clinical trial reaches new milestone appeared first on ThaiPR.NET.

]]>